Alkem Laboratories Stock Screener | Share Price & Fundamental Analysis
ALKEM
Pharmaceuticals
Screen Alkem Laboratories share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹5806.50
▲
151.00 (2.67%)
Share Price BSE
₹5790.30
▲
138.05 (2.44%)
Market Cap
₹69,425.42 Cr.
P/E Ratio (TTM)
28.04
P/B Ratio
5.06
EPS (TTM)
₹181.11
Dividend Yield
0.80%
Debt to Equity
0.13
52W High
₹5806.50
52W Low
₹4563.70
Operating Margin
12.00%
Profit Margin
9.79%
Revenue (TTM)
₹3,290.00
EBITDA
₹537.00
Net Income
₹322.00
Total Assets
₹17,691.00
Total Equity
₹12,434.00
Alkem Laboratories Share Price History - Stock Screener Chart
Screen ALKEM historical share price movements with interactive charts. Analyze price trends and patterns.
Alkem Laboratories Company Profile - Fundamental Screener
Screen Alkem Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ALKEM shares.
Alkem Laboratories Limited is an Indian pharmaceutical company headquartered in Mumbai, with global operations. The company develops, manufactures, and sells pharmaceutical and nutraceutical products, including branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals. It has a portfolio of over 800 brands in India and operates in more than...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Basudeo N Singh
ISIN
INE540L01014
Website
https://www.alkemlabs.com
Alkem Laboratories Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen ALKEM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 17,691 | 15,575 | 13,757 | 14,069 | 11,519 | 9,946 | 8,208 | 7,666 | 6,568 | 5,535 |
| Current Assets | 10,811 | 10,412 | 8,730 | 8,434 | 6,929 | 5,506 | 4,216 | 4,013 | 2,917 | 2,769 |
| Fixed Assets | 2,852 | 2,873 | 2,683 | 2,902 | 2,793 | 2,908 | 2,530 | 2,284 | 1,797 | 1,450 |
| Liabilities | ||||||||||
| Total Liabilities | 17,691 | 15,575 | 13,757 | 14,069 | 11,519 | 9,946 | 8,208 | 7,666 | 6,568 | 5,535 |
| Current Liabilities | 1,299 | 866 | 615 | 417 | 357 | 392 | 446 | 297 | 296 | 210 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 12,434 | 10,714 | 9,435 | 8,847 | 7,558 | 6,309 | 5,572 | 4,985 | 4,583 | 3,787 |
| Share Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves & Surplus | 11,961 | 10,288 | 9,021 | 8,614 | 7,353 | 6,137 | 5,415 | 4,840 | 4,444 | 3,668 |
Screen ALKEM income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,290 | 3,521 | 4,105 | 3,024 | 3,152 | 3,549 | 3,467 | 2,971 | 3,034 | 3,503 | 3,418 | 2,504 | 2,628 | 3,130 | 3,086 |
| Expenses | 2,753 | 2,632 | 3,080 | 2,546 | 2,423 | 2,662 | 2,615 | 2,652 | 2,579 | 2,751 | 2,668 | 2,162 | 2,373 | 2,626 | 2,442 |
| EBITDA | 537 | 889 | 1,025 | 478 | 729 | 887 | 852 | 319 | 455 | 752 | 750 | 343 | 255 | 505 | 644 |
| Operating Profit % | 12.00% | 22.00% | 23.00% | 13.00% | 20.00% | 22.00% | 23.00% | 9.00% | 13.00% | 20.00% | 20.00% | 13.00% | 8.00% | 15.00% | 20.00% |
| Depreciation | 113 | 88 | 94 | 83 | 81 | 79 | 85 | 78 | 72 | 74 | 70 | 83 | 76 | 77 | 78 |
| Interest | 28 | 30 | 35 | 27 | 29 | 28 | 36 | 29 | 30 | 30 | 26 | 17 | 27 | 25 | 27 |
| Profit Before Tax | 396 | 771 | 896 | 367 | 619 | 780 | 731 | 212 | 353 | 648 | 655 | 243 | 152 | 402 | 539 |
| Tax | 74 | 103 | 117 | 63 | 69 | 78 | 90 | 144 | 65 | 33 | 51 | 135 | 20 | 55 | 79 |
| Net Profit | 322 | 668 | 779 | 305 | 550 | 702 | 641 | 68 | 288 | 615 | 604 | 108 | 131 | 348 | 460 |
| EPS | 25.57 | 55.56 | 63.99 | 24.55 | 45.60 | 57.60 | 52.34 | 5.94 | 23.98 | 51.90 | 49.76 | 9.00 | 10.68 | 27.67 | 38.03 |
Alkem Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen ALKEM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,913 | 1,948 | 1,683 | 1,111 | 1,265 | 585 | 780 | 266 | 471 | 726 |
| Investing Activities | -1,288 | -1,011 | 120 | -1,433 | -995 | -737 | -318 | -351 | -294 | 205 |
| Financing Activities | -811 | -1,145 | -1,761 | 380 | -272 | 79 | -379 | 85 | -138 | -927 |
| Net Cash Flow | -186 | -208 | 42 | 58 | -2 | -73 | 82 | 0 | 40 | 3 |
Screen ALKEM shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 55.13% | 53.04% | 51.20% | 56.74% | 56.38% | 55.66% | 55.66% | 57.16% |
| FII Holding | 9.41% | 9.11% | 9.48% | 9.11% | 8.69% | 9.02% | 10.15% | 0.00% |
| DII Holding | 19.42% | 21.80% | 21.93% | 15.63% | 18.57% | 19.21% | 18.01% | 16.69% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 15.77% | 15.69% | 17.18% | 18.31% | 16.15% | 15.84% | 15.90% | 21.44% |
| Other Holding | 0.28% | 0.36% | 0.22% | 0.21% | 0.21% | 0.26% | 0.28% | 4.71% |
| Shareholder Count | 84,326 | 79,740 | 67,196 | 65,830 | 69,627 | 74,744 | 84,038 | 73,440 |
Alkem Laboratories Dividend Screener - Share Yield Analysis
Screen ALKEM dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹45.00 | 0.80% |
| 2024-March | ₹40.00 | 0.82% |
| 2023-March | ₹50.00 | 1.01% |
| 2022-March | ₹34.00 | 1.03% |
| 2021-March | ₹30.00 | 0.83% |
| 2020-March | ₹25.00 | 0.90% |
| 2019-March | ₹16.00 | 0.69% |
| 2018-March | ₹13.00 | 0.74% |
| 2017-March | ₹15.00 | 0.75% |
Alkem Laboratories Index Membership - Market Screener Classification
Screen ALKEM by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Alkem Laboratories Market Events Screener - Corporate Actions
Screen ALKEM market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 3.87% |
| 2025-08-25 | 2025-08-25 | Annual General Meeting | NA | 3.04% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -1.07% |
| 2025-08-08 | 2025-08-08 | Dividend | ₹ 8.00 /share | -7.36% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | -0.47% |
| 2025-02-14 | 2025-02-14 | Dividend | ₹ 37.00 /share | -10.16% |
| 2025-02-07 | 2025-02-07 | Quarterly Result Announcement | NA | 6.10% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -5.09% |
| 2024-08-30 | 2024-08-30 | Annual General Meeting | NA | 12.88% |
| 2024-08-09 | 2024-08-10 | Dividend | ₹ 5.00 /share | 9.01% |
| 2024-02-16 | 2024-02-17 | Dividend | ₹ 35.00 /share | 2.54% |
| 2023-08-10 | 2023-08-10 | Dividend | ₹ 10.00 /share | 27.09% |
| 2023-02-17 | 2023-02-18 | Dividend | ₹ 15.00 /share | 1.06% |
| 2023-02-17 | 2023-02-18 | Dividend | ₹ 25.00 /share | 1.06% |
| 2022-08-08 | 2022-08-10 | Dividend | ₹ 4.00 /share | 0.84% |
Alkem Laboratories Competitors Screener - Peer Comparison
Screen ALKEM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,705 | 40.28 | 54,729 | 9.71% | 10,980 | 58.99 |
| Divis Laboratories | 176,338 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 138,499 | 62.26 | 11,539 | 6.99% | 1,911 | 80.95 |
| Cipla | 118,573 | 22.75 | 28,410 | 7.12% | 5,291 | 38.52 |
| Dr Reddys Laboratories | 103,728 | 18.27 | 33,741 | 16.73% | 5,725 | 40.17 |
| Lupin | 101,149 | 22.61 | 22,910 | 13.74% | 3,306 | 71.67 |
| Mankind Pharma | 95,432 | 52.17 | 12,744 | 20.90% | 2,007 | 64.16 |
| Zydus Life Science | 93,333 | 18.63 | 23,511 | 18.55% | 4,615 | 52.14 |
| Aurobindo Pharma | 71,752 | 20.91 | 32,346 | 9.43% | 3,484 | 61.25 |
| Alkem Laboratories | 69,425 | 28.04 | 13,458 | 3.70% | 2,216 | 63.97 |
Alkem Laboratories Company Announcements - News Screener
Screen ALKEM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-02 | Disclosure Under Regulation 30 Of SEBI LODR | View |
| 2026-01-01 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | View |
| 2025-12-31 | Disclosure Under Regulation 30 Of SEBI LODR. | View |
| 2025-12-31 | Disclosure Under Regulation 30 Of SEBI LODR. | View |
| 2025-12-31 | Disclosure Under Regulation 30 Of SEBI LODR. | View |
| 2025-12-30 | Disclosure Under Regulation 30 Of SEBI LODR. | View |
| 2025-12-26 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2025-12-26 | Disclosure Under Regulation 30 Of SEBI. | View |
| 2025-12-23 | Closure of Trading Window | View |
| 2025-12-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-16 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-12 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-10 | GMP Inspection By Malta Medicines Authority At CompanyS Manufacturing Facility Located At Daman India | View |
| 2025-12-08 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-08 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-05 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-05 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-04 | Disclosure Under Regulation 30 Of SEBI . | View |